473 W 12th Ave
Columbus, OH 43210
Phone: (614) 293-4967
I have had the fortune to have had a very strong career path since joining the faculty at OSU, having trained under fine physicians at Northwestern University and the Ohio State University. I began practice in July 2011. In the spring of 2012, I was offered the chance to become OSU’s Clinical Director of the Lipid Clinic. I passed the certification exam in Lipidology in 2012 and became one of the few cardiologists nationwide certified in both cardiology and lipidology. I single-handedly have seen the majority of lipid clinic patients during my time as Director and believe I have enriched the quality of care. The level of complexity in lipid management that the lipid clinic routinely sees has been commented favorably upon often. In the lipid clinic, we see patients such as those with familial hypercholesterolemia (FH), hypertriglyceridemia, HIV patients with dyslipidemia, and patients particularly interested in prevention of cardiovascular disease (CVD). Our unique team-based approach of physician with expert pharmacist is one reason why we provide such excellent care. A team of us presented at Internal Medicine Grand Rounds and received email congratulations stating, “You have a lot to be proud of and with your efforts you make our Medical Center a stronger place.” We routinely see patients from outside Ohio State who come specifically for our expert care, with individuals routinely driving in hundreds of miles.
Our quality can be demonstrated in multiple ways. Among patients seen three times from October 2011 to June 30, 2013, initially a new patient, the mean LDL fell from 148 mg/dL to 108.5 mg/dL; based on large meta-analyses of cholesterol trials, a reduction of 40 mg/dL reduced major adverse cardiac events by 25%. In addition, our clinic model has been so favorably viewed that outsiders wish to learn from and partner with us (as exemplified from visit from Indiana University cardiologist Dr. Julie Clary and team), and the proposed partnership with the FH Foundation. The FH foundation is a national non-profit organization dedicated to improving management of FH, a genetic disorder resulting in premature CVD. A partnership with Ohio State has been proposed, with myself as the lead physician.
I have been recognized as a leader, serving on the Operations Council for the Ross Heart Hospital and being described by a prominent physician within the medical center as a leader and one to which others look up. In 2015, I was named the Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics. In this role, I am responsible for promoting the Prevention of Cardiovascular Disease, as well as being the Medical Director of Cardiac rehabilitation. Cardiac rehabilitation is an insurance-reimbursed program for patients post-cardiac surgery, post-heart attack and with heart failure. I meet regularly with the staff of cardiac rehabilitation. I was named Regional Representative to the Midwest Lipid Association, Midwest branch of the National Lipid Association. I am also on the Editorial board of acc.org, authoring and reviewing content for the site, the primary teaching and educational source for cardiologists and cardiologists in training, nationwide. Furthermore, I was recently invited to serve on the Ohio Commission on Minority Health, Expert Panel on Obesity. Obesity rates are high in Ohio and an overwhelming burden of obesity and cardiovascular disease risks falls on minorities. I have been asked to speak on numerous occasions, at various Grand Rounds in the medical center, in Ohio, in the community, and via Webcasts.
My mission is to push Preventive Cardiology at Ohio State to even greater heights. I have generated a proposal for a Preventive Cardiology Center. Charged to create the very best business plan of such a center, modeled on the very finest, I went on a month-long “voyage” of sorts, speaking to national leaders, such as Dr. Lawrence Sperling of Emory, current president of American Society of Preventive Cardiology, and Dr. Roger Blumenthal of Johns Hopkins as well as meeting some of the top leaders in Ohio State to garner their vision.
My experiences as both a cardiologist and lipidologist, with significant amounts of clinical time in each arena, have given me a unique and powerful view of CVD and its risk factors. Few others have had the experience I have had in clinical cardiology work, from imaging in echocardiography and nuclear cardiology, and lipidology, having seen a significant number of patients with complex lipid disease.
|2008 - present||Internal Medicine: American Board of Internal Medicine|
|2010 - present||Testamur of Certification of Nuclear Board of Cardiology: Certification Board of Nuclear Cardiology|
|2011 - present||Cardiovascular Medicine: American Board of Internal Medicine|
|2012 - present||Diplomate: American Board of Clinical Lipidology|
Sharma, Kavita. "Dyslipidemia." In Color Atlas of Heart Failure. Edited by Ragavendra Baliga. -. January 0.
Sharma, K. "Dyslipidemia." In Color Atlas of Heart Failure. -. January 0.
Sharma, K. "Secondary Prevention of Cardiovascular Disease." In Practical Cardiology, 3rd Edition. -. January 0.
Sharma, K. "Primary Prevention of Cardiovascular Disease." In Practical Cardiology, 3rd Edition. -. January 0.
Sharma, K. "Management of High Triglycerides." In Dyslipidemia: A Clinical Approach. -. January 0.
Sharma, Kavita; Gulati, Martha. "Heart Disease in Women." In Color Atlas and Synopsis of Women's Cardiovascular Health. Edited by William T. Abraham. -. New York: McGraw Hill Education, August 2014.
Sharma, Kavita. "The Evaluation of Valvular Heart Disease." In Color Atlas and Synopsis of Echocardiography. Edited by William T. Abraham. -. New York: McGraw Hill Education, January 2015.
|2001||None Indicated, Northwestern University|
|2005||B.A., Northwestern University Feinberg School of Medicine|
|2015 - present||American College of Cardiology e-learning|
|2015 - 2016||Global Heart Journal|
|2016 - present||Correlation of carotid artery reactivity with cardiovascular risk factors and coronary artery vasodilator responses in asymptomatic, healthy volunteers|
|2001 - present||Honors Program in Medical Education. Northwestern Feinberg School of Medicine.|
|2010 - 2011||Chief Fellow. The Ohio State University Medical Center.|
|2011 - present||Mayo Clinic Echo Board Review Fellow Scholarship. Mayo Clinic.|
|2011 - present||2nd place, Clinical Fellow Research Day Poster Competition. The Ohio State University Medical Center.|
|2012 - present||Patient Satisfaction for years 2012, 2013, 2015, 2016. Gahanna Cardiology.|
|2012 - present||Patient Satisfaction for years 2012, 2013, 2015, 2016. Richard M. Ross Heart Hospital.|
Sharma, K; Nissen, S; Mukherjee, D. "Genetics of Dyslipidemia and Ischemic Heart Disease." Current Cardiology Reports. (January 0.): -.
Sharma, K; Gulati, M. "Women and Primary Prevention of CVD with Statins." LipidSpin. (January 0.): -.
Ertel,Drew; Phatak,Kavita; Makati,Kevin; Holland,Marian; Baig,Sara; Kim,Michael,H; Link,Mark; Passman,Rod. "Predictors of Early Mortality in Patients Age 80 and Older Receiving Implantable Defibrillators." PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY. Vol. 33, no. 8. (August 2010.): 981-987.
Ertel D; Phatak K; Makati K; Holland M; Baig S; Kim MH; Link M; Passman R. "Predictors of early mortality in patients age 80 and older receiving implantable defibrillators.." Pacing And Clinical Electrophysiology: PACE. Vol. 33, no. 8. (August 2010.): 981-.
Raman,Subha,V; Phatak,Kavita; Hoyle,J,Chad; Pennell,Michael,L; McCarthy,Beth; Tran,Tam; Prior,Thomas,W; Olesik,John,W; Lutton,Anthony; Rankin,Chelsea; Kissel,John,T; Al-Dahhak,Roula. "Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome." EUROPEAN HEART JOURNAL. Vol. 32, no. 5. (March 2011.): 561-567.
Raman SV; Phatak K; Hoyle JC; Pennell ML; McCarthy B; Tran T; Prior TW; Olesik JW; Lutton A; Rankin C; Kissel JT; Al-Dahhak R. "Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.." European Heart Journal. Vol. 32, no. 5. (March 2011.): 561-.
Sharma,Kavita; Kohli,Priya; Gulati,Martha. "An update on exercise stress testing.." Current problems in cardiology. Vol. 37, no. 5. (May 2012.): 177-202.
Sharma,Kavita; Gulati,Martha. "Coronary artery disease in women: a 2013 update.." Global Heart. Vol. 8, no. 2. (June 2013.): 105-112.
Sharma, K; Gulati, M. "Women and Primary Prevention of CVD with Statins." LipidSpin. Vol. 13, no. 3. (June 2015.): 16-.
Sharma, Kavita; Gulati, Martha. "Recent Trials Regarding Exercise and Cardiovascular Outcomes." LipidSpin Online Publication. Vol. 13, (July 2015.): online publication-.
Gulati,Martha; Sharma,Kavita. "MY APPROACH to elevated cholesterol in women.." Trends in cardiovascular medicine. Vol. 26, no. 4. (May 2016.): 389-390.
|October 2014||Sharma, K; Maffett, S."MedNet 21 - Coronary Artery Disease; Management and diagnostic testing"|
|March 2015||Sharma, K."Cholesterol Management" livescience.com|
"A priming mechanism corrects the slowing of O2 uptake kinetics by leg tourniquets." Presented at American Physiology Society, . (January 2004)
"Should All Octogenarians Who Meet Criteria Receive an ICD?." Presented at AHA Scientific Session, . (January 2007)
"Fast Ventricular Tachycardia at Programmed Electrical Stimulation as a Risk factor for Spontaneous Ventricular Arrhythmias in Implantable Cardioverter Defibrillator Patients." Presented at Central Society for Clinical Research, . (January 2007)
"Fast Ventricular Tachycardia at Programmed Electrical Stimulation as a Risk factor for Spontaneous Ventricular Arrhythmias in Implantable Cardioverter Defibrillator Patients." Presented at 2007 Illinois Regional ACP Associates Day, . (January 2007)
"Fast Ventricular Tachycardia at Programmed Electrical Stimulation as a Risk factor for Spontaneous Ventricular Arrhythmias in Implantable Cardioverter Defibrillator Patients." Presented at Midwestwern Section American Federation for Medical Research, . (January 2007)
"Subclinical Myocardial Ischemia without LV Hypertrophy in Friedreich's Ataxia." Presented at AHA Scientific Sessions 2009, . (January 2009)
"Myocardial Ischemia and Fibrosis in Friedreich Ataxaia: A Mitochondrial cardiomyopathy with Metabolic Syndrome." Presented at Ohio ACC, . (January 2010)
"The Effect of GLP-1 Receptor Agonists on Targets for Cardiovascular Risk Reduction. Abstract accepted for poster presentation." Presented at American College of Clinical Pharmacy Annual Meeting, . (October 2013)
"Impact of adherence to medication and lifestyle factors in reducing cardiovascular risk in a patient with familial hypercholesterolemia." Presented at 2014 Midyear Clinical Meeting American Society of Health-System Pharmacists, . (June 2014)
"Pharmacist-Physician Collaboration in a Specialty Lipid Clinic Treating Patients with Stating Intolerances." Presented at American Pharmacists Asociation annual meeting, . (March 2014)
"Pharmacist-Physician Collaboration in a Specialty Lipid Clinic Treating Patients with Statin Intolerances." Presented at American Pharmacists Association annual meeting, . (March 2014)
"Lipid Management - Invited to present." Presented at OSU 2016 Multi-Disciplinary Cardiovascular Conference, Orlando. (September 2016)
""Find FH" - Invited to present." Presented at 4th Annual Familial Hypercholesterolemia (FH) Global Summit, Dallas. (October 2016)
"Cardiovascular Disease and Nutrition - Invited to present." Presented at Cardiovascular Emergencies Regional Conference, . (September 2016)
"Description of Discordance between LDL cholesterol, non-HDL cholesterol and LDL particle number among patients in a lipid clinic." Presented at National Lipid Association, . (May 2016)
"Early experience with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors in patients treated in an outpatient lipid clinic." Presented at National Lipid Association, . (May 2016)
|present||ABC6 TV appearance.|
Sabato, L, PharmD; Snider, M, PharmD; Sharma, K, MD; Gulati, M, MD. Pharmacist-physician collaboration in a specialty lipid clinic treating patients with statin intolerances. April 2016.
Gaborcik, J, PharmD; Snider, M, PharmD, Hevezi, M, PharmD; Wehr, A, MS; Sharma, K, MD. Description of Discordance between LDL cholesterol, non-HDL cholesterol and LDL particle number among patients in a lipid clinic. April 2016.